We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The World Health Organization (WHO) is working on an international pandemic response accord that would, in part, require pharmaceutical companies to publicly disclose prices or deals for any of their products that might be used in future health emergencies. Read More
Richmond, Va.-based Indivior, maker of the opioid treatment Suboxone (buprenorphine-naloxone), has announced plans to purchase Opiant Pharmaceuticals, a Santa Monica, Calif., producer of the opioid overdose nasal spray Narcan (naloxone), in a deal valued at $145 million. Read More
Richmond, Va.-based Indivior, maker of the opioid treatment Suboxone (buprenorphine-naloxone), has announced plans to purchase Opiant Pharmaceuticals, a Santa Monica, Calif., producer of the opioid overdose nasal spray Narcan (naloxone), in a deal valued at $145 million. Read More
AbbVie has filed a complaint against several generics producers — including Teva Pharmaceuticals and Novartis’ Sandoz unit — alleging the companies infringed on patents for its endometriosis drug Orilissa (elagolix) by planning to make generic alternatives. Read More
Takeda, Zedira and Dr. Falk Pharma inked a collaboration and licensing agreement to develop TAK-227, an investigational therapy for patients with celiac disease, an autoimmune disorder characterized by inability to tolerate gluten. The therapy currently is undergoing a phase 2b trial. Read More
Eli Lilly plans to further expand into gene therapies with the $487 million purchase of Massachusetts-based biotech Akouos, a company developing gene treatments for hearing loss. Read More